SELUTION DeNovo Trial Results
The SELUTION DeNovo randomized clinical trial, presented at TCT 2025 in San Francisco, USA, demonstrated non-inferiority of a drug-eluting balloon to standard-of-care for in-stent restenosis.
A percutaneous coronary intervention (PCI) strategy using the SELUTION SLR sirolimus-eluting balloon (SEB) with provisional stenting was found to be non-inferior to the systematic use of drug-eluting stents (DES) for the treatment of de novo coronary lesions at one year.
Drug-eluting stents remain the mainstay of PCI, but are associated with a persistent annual 2–4% rate of very-late adverse cardiovascular events.
- The trial was conducted across 62 participating sites in 12 countries in Europe and Asia.
- The study aimed to test whether a stent-minimizing approach could achieve outcomes comparable to standard DES implantation.
Author's summary: Trial shows non-inferiority of drug-eluting balloon to standard care.
More News
- Leonard Green acquires Epiphany Dermatology from CI | PE Hub
- Art the Clown Owes One of His 'Terrifier' Victims a Lot of Money
- NGP-backed Cygnet Energy to buy Kiwetinohk Energy for $1bn | PE Hub
- Materialise drives personalised surgery from niche to norm
- Banging bumper fun from 2000AD!
- Gates Champions Human Welfare Over Climate Alarmism Narrative
- New president of The Church of Jesus Christ of Latter-day Saints inherits a global faith far more diverse than many realize – Baptist News Global
- Art the Clown Owes One of His 'Terrifier' Actresses a Lot of Money
- Redefining surgical access: How ASCs transform the healthcare ecosystem - Becker’s ASC
- 'Chainsaw Man - The Movie: Reze Arc' Review — A Beautifully Chaotic Anime